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ABSTRACT
Introduction The newer glucose- lowering therapies 
for type 2 diabetes (T2D), the glucagon- like peptide-1 
receptor agonists (GLP1- RAs) and the sodium- glucose 
co- transporter 2 inhibitors (SGLT2i), have additional clinical 
benefits beyond improving glycaemic control; promoting 
weight loss, addressing associated cardiovascular risk 
factors and reducing macrovascular and microvascular 
complications. Considering their independent mechanisms 
of actions, there is a potential for significant synergy with 
combination therapy, yet limited data exist. This 32- week 
randomised, double- blind, placebo- controlled trial will gain 
mechanistic insight into the effects of coadministration 
of exenatide QW, a weekly subcutaneous GLP1- RA, with 
dapagliflozin, a once daily oral SGLT2i, on the dynamic, 
adaptive changes in energy balance, total, regional and 
organ- specific fat mass and multiorgan insulin sensitivity.
Methods and analysis 110 obese patients with 
diagnosed T2D (glycated haemoglobin, HbA
1c ≥48 mmol/
mol) will be treated for 32 weeks with dapagliflozin 
(10 mg once daily either alone or in combination with 
exenatide QW (2 mg once weekly); active treatments will 
be compared with a control group (placebo tablet and 
sham injection). The primary objective of the study is to 
compare the adjusted mean reduction in total body fat 
mass (determined by dual- energy X- ray absorptiometry, 
DEXA) from baseline following 32 weeks of treatment with 
exenatide QW and dapagliflozin versus dapagliflozin alone 
compared with control (placebo). Secondary outcome 
measures include changes in (1) energy balance (energy 
intake and energy expenditure measured by indirect 
calorimetry); (2) appetite (between and within meals) 
and satiety quotient; (3) body composition including 
visceral adipose tissue, subcutaneous adipose tissue, 
liver and pancreatic fat. Exploratory outcome measures 
include metabolic changes in hepatic and peripheral 
insulin sensitivity (using a two- stage hyperinsulinaemic, 
euglycaemic clamp), central nervous system responses to 
food images using blood oxygen level- dependent (BOLD) 
functional MRI (fMRI) and changes in cardiovascular 
function (using transthoracic echocardiography, cardiac 
MR and duplex ultrasonography).
Ethics and dissemination This study has been approved 
by the North West Liverpool Central Research Ethics 
Committee (14/NW/1147) and is conducted in accordance 
with the Declaration of Helsinki and the Good Clinical 
Strengths and limitations of this study
 ► This is the first study to assess the effects of 
sodium- glucose co- transporter 2 inhibitor (SGLT2i) 
and glucagon- like peptide-1 receptor agonist 
(GLP1- RA) combination therapy on changes in body 
composition and appetite in a randomised controlled 
trial design incorporating short- term and long- term 
effects.
 ► We employ an array of experimental techniques 
to identify the underlying biological basis of these 
changes and to yield some mechanistic insight into 
the metabolic, cardiac and vascular effects of com-
bination therapy.
 ► The study is not designed to examine the individual 
effects of each agent but rather to investigate the 
compensatory mechanisms that additional GLP-1 
RA therapy to SGLT2i therapy may induce.
 ► The relatively small sample size provides sufficient 
power to answer the primary research question.
 ► The relatively low sensitivity of even ‘state- of- the- 
art’ research methods for detecting changes in en-
ergy intake, expenditure and energy balance mean 
that subtle changes may be missed.
2 Brown E, et al. BMJ Open 2021;11:e045663. doi:10.1136/bmjopen-2020-045663
Open access 
Practice. Results from the study will be published in peer- reviewed 
scientific and open access journals and/or presented at scientific 
conferences and summarised for distribution to the participants.
Trial sponsor University of Liverpool.
Trial registration number ISRCTN 52028580; EUDRACT number 2015-
005242-60.
BACKGROUND AND RATIONALE
Type 2 diabetes (T2D) is closely related to obesity: their 
prevalence is rising in parallel, synergistically accelerating 
and increasing the severity of diabetes- related compli-
cations.1 Weight loss is therefore a primary therapeutic 
target in the management of patients with T2D. While 
some glucose- lowering treatments are associated with 
weight gain (eg, sulfonylureas, thiazolidinediones and 
insulin), two recent classes of therapeutic agents for T2D, 
namely, the glucagon- like peptide-1 receptor agonists 
(GLP1- RAs) and the sodium- glucose co- transporter 2 
inhibitors (SGLT2i), are associated with weight loss, 
achieved via different mechanisms: increased urinary 
glucose loss for SGLT2i, and promotion of satiety for 
GLP-1 RAs.
Pharmacological inhibition of SGLT2 reduces renal 
glucose reabsorption in an insulin- independent mecha-
nism promoting a daily urinary glucose excretion (UGE) 
of ~75 g, an energy deficit of ~300 kcal and a diuresis of 
~400 mL.2 3 GLP1- RAs confer similar therapeutic bene-
fits operating via distinct mechanisms: improving glycaemic 
control (by enhancing glucose- dependent insulin secre-
tion and inhibiting hepatic glucose production)4 and 
reducing body weight via a central effect (promoting satiety 
via the hypothalamus).5 6 The glucose- lowering effects 
of SGLTi maybe attenuated by increased endogenous 
(hepatic) glucose production,7 8 partially explained by 
a compensatory hyperglucagonaemia.9 It is also unclear 
why the magnitude of weight loss with SGLT2i therapy is 
not commensurate with the expected weight loss based 
on the determined caloric loss, suggesting compensatory 
or adaptative changes in energy intake and energy expen-
diture that attenuate the energy imbalance.10 11
Overall, the limited available evidence demonstrates 
the additive benefits of combination therapy with a GLP-1 
RA and SGLT2 inhibitor on glycaemic improvement 
and weight.12–14 Further studies are needed to elucidate 
their combined effects on metabolic and cardiovascular 
disease. The central hypothesis of this mechanistic study 
is that coadministration of exenatide once weekly (QW; a 
GLP-1 RA) with dapagliflozin (an SGLT2i) treatment will 
offset the potentially (mal)adaptive compensatory meta-
bolic and appetitive responses occurring with dapagli-
flozin alone. Specifically, we anticipate that GLP-1 RAs 
can attenuate the increased hepatic glucose production 
due to hyperglucagonaemia and possible compensa-
tory increases in appetite that arise with SGLT2i therapy 
(figure 1).
PRIMARY OBJECTIVE
The primary objective of the study is to compare the 
adjusted mean reduction in total body fat mass (deter-
mined by dual- energy X- ray absorptiometry, DEXA) 
from baseline following 32 weeks of treatment with exen-
atide QW and dapagliflozin versus dapagliflozin alone 
compared with control (placebo).
SECONDARY OBJECTIVES
The key secondary objectives are to assess the adjusted 
mean change from baseline of:
1. Metabolic measures
 – HbA1c (mmol/mol).
 – Fasting glucose (mmol/L).
 – Total Low- density lipoproteins (LDL) and High- 
density lipoproteins (HDL) cholesterol and triglyc-
erides (mmol/L).
Figure 1 Potential synergy with sodium- glucose co- transporter 2 (SGLT2) inhibitors and glucagon- like peptide-1 (GLP-1) 
receptor agonists.
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 – Twenty- four hour urinary glucose excretion(UGE) 
(g/dL).
2. Changes in energy balance
 – Food intake (g and kcal) at ad libitum meals.
 – Total energy expenditure: Measured by indirect cal-
orimetry using a ventilated hood system and derived 
using the Weir equation.15 16
 – Physical activity: Measured by a multisensor array 
(daily average step count, and time spent in do-
mains of physical activity (METS)).
3. Eating behaviour
 – Visual Analogue Scale (VAS): A seven- component 
VAS questionnaire used to assess hunger, fullness, 
prospective food consumption and desire to eat.
 – Satiety quotient: Measured using VAS ratings and 
calculated as the difference in hunger pre- meal and 
post- meal divided by the within meal caloric intake.
 – Psychology of appetite questionnaire scores.
4. Changes in body composition
 – Reduction in total body weight (kg).
 – Total fat volume (L), regional fat volumes (visceral 
fat and subcutaneous fat volume) and tissue- specific 
fat content (liver and pancreatic fat) measured by 
MRI scanning.
 – Changes in lean body mass measured by DEXA and 
MRI.
5. Changes in cardiovascular variables
 – Blood pressure (mm Hg).
In addition, this study will assess treatment compliance 
at 28- day intervals, based on the number of injections 
administered and returned tablet counts.
EXPLORATORY ENDPOINTS
These are to be analysed and presented separately to 
primary and secondary outcome measures.
1. Metabolic measures
 – Endogenous (hepatic) glucose production, during 
a euglycaemic low- dose insulin clamp combined 
with a constant infusion of [6,6 2H2] glucose.
 – Peripheral insulin sensitivity, measured by glucose 
uptake (Rd) and glucose metabolic clearance rate 
(MCR), during a euglycaemic high- dose insulin 
clamp combined with a constant infusion of [6,6 
2H2] glucose.
2. Changes in energy balance
 – Total energy expenditure: Measured by doubly la-
belled water.
3. Changes in cardiovascular variables:
 – Echocardiographic derived measures of left and 
right ventricular structure and function, including 
systolic and diastolic strain (rate) and twist mechan-
ics.
 – Carotid artery intima media thickness (cIMT; mm) 
and brachial artery flow- mediated dilatation (FMD) 
using duplex ultrasonography.
 – MRI derived measures of cardiac structure and 
function.
4. Changes in body composition
 – Liver fibrosis measured by multiparametric MRI 
scanning.
5. Changes in Central nervous system (CNS) response
 – Differences in neuronal activity in CNS reward and 
satiety circuits (including striatum, amygdala, orb-
itofrontal cortex, insula, hypothalamus) as repre-
sented by BOLD (blood oxygen level- dependent) 
functional MRI (fMRI) signal change.
SAFETY OBJECTIVE
The type and frequency of adverse events will be reported 
for all treatment groups.
METHODS AND ANALYSIS
Overall design, investigational plan and study population
This is a 32- week outpatient, double- blind, parallel group, 
randomised placebo- controlled mechanistic study of 
exenatide QW (GLP1- RA) and dapagliflozin (SGLT2i) 
treatment. One hundred and ten participants with obesity 
and T2D will be recruited: male and female, aged 18–65 
years, Body mass index (BMI) 30–50 kg/m2, with glycated 
haemoglobin (HbA1c) ≥6.5% but ≤11% (48–97 mmol/
mol; see table 1 for complete criteria). Each participant 
will have 13 study visits. Participants will be randomised 
equally to each of the three treatment arms (figure 2).
Patient and public involvement
Patients were involved in the design and conduct of the 
trial. During the feasibility stage, choice of outcome 
measures, the number of study visits and methods of 
recruitment were informed through discussions with 
patients in the clinical setting and attendance at local 
diabetes education sessions. During the trial, a patient 
joined the independent trial steering committee (TSC). 
Once the trial has been published, a clear ‘plain English’ 
summary of the findings will be created so that they are 
widely available to participants and the wider patient 
groups. These will be presented to attendees at diabetes 
awareness days at the hospital and within the community.
Sample size
This trial will examine exenatide QW, a weekly GLP1- RA, 
added to dapagliflozin versus sham saline injection added 
to dapagliflozin for an intervention period, of 32 weeks 
compared with a control group (placebo tablet and sham 
injection).
 ► Arm A: Placebo tablet once daily and sham injection 
once weekly.
 ► Arm B: SGLT2 (dapagliflozin 10 mg once daily plus 
sham injection once weekly).
 ► Arm C: SGLT2+GLP1 RA (dapagliflozin 10 mg plus 
exenatide 2 mg once weekly injection).
The sample sizes have been calculated in order to 
conduct the following two comparisons:
i. Arm B (dapagliflozin) vs A (placebo).
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ii. Arm B (dapagliflozin) vs C (dapagliflozin and 
exenatide).
These comparisons are selected to answer the key 
question of interest; although the study will not provide 
comparisons between arms C and A, nor will they be 
reported.
The original sample size calculation was carried out 
using Stata V.14 software (Stata Statistical Software: Release 
14. College Station, Texas, USA: StataCorp LP). For both 
comparisons, a 1.5 kg in the change in body fat mass is 
considered a clinically relevant difference. From previous 
data, the within patient SD for the change in total body 
fat between baseline and 32 weeks is estimated as 1.8 kg.17 
From this, a between- patient SD of 2.55 kg was computed. 
Using a two- group test with equal means (assuming 80% 
power and one- sided 5% significance level), 36 patients 
per treatment arm were estimated to be required in order 
to adequately power the planned analysis (assuming 
effect size of 0.59). Using these calculations and an antici-
pated 10% attrition and patient dropout rate, the original 
sample size was set at 120 participants.
As a result of the COVID-19 pandemic, however, 15 
active patients were lost to follow- up and a revised sample 
size calculation was implemented, reducing the original 
sample size from 120 patients to 110 randomised patients 
in order to maintain meaningful results within the 
Table 1 Study inclusion and exclusion criteria
INCLUSION CRITERIA
 ► Males or females, age 18–65 years.
 ► A clinical diagnosis of type 2 diabetes.
 ► Glycosylated haemoglobin (HbA1c) ≥6.5% but ≤11% (48–97 mmol/mol).
 ► Currently treated with either diet or any combination of metformin, DPP- IV 
inhibitors* and sulfonylureas (excluding patients treated with pioglitazone or 
insulin). *DPP- IV inhibitors will require wash out period of 4 weeks.
 ► BMI 30–50 kg/m2.
 ► Patients who are receiving the following medications must be on stable 
treatment regimen for a minimum of 2 months prior to screening:
 – Thyroid hormone replacement
 – Antidepressants
EXCLUSION CRITERIA
Medical History and Concurrent Diseases
 ► Type 1 diabetes mellitus.
 ► History of diabetic ketoacidosis or hyperosmolar non- ketotic coma.
 ► Renal impairment: eGFR less than 60 mL/min/1.73 m2.
 ► Familial renal glucosuria.
 ► Clinically significant abnormal free T4 or patients needing initiation or 
adjustment of thyroid treatment according to the investigator.
 ► Severe uncontrolled hypertension ≥180 mm Hg and/or diastolic ≥110 mm Hg.
 ► Congestive heart failure class III- IV.
 ► Recent (<6 months) myocardial infarction.
 ► Known chronic liver disease (other than hepatic steatosis).
 ► Significant cardiac dysrhythmias (including pacemaker or ICD).
 ► Previous stroke.
 ► History of seizures or unexplained syncope.
 ► History of, or currently have, acute or chronic pancreatitis.
 ► History of malignancy (with the exception of basal and squamous cell 
carcinoma of the skin) within the last 5 years.
 ► History of medullary thyroid carcinoma or MEN2 (Multiple endocrine neoplasia 
type 2) or family history of medullary thyroid carcinoma or MEN2.
 ► History of gastric bypass surgery or gastric banding surgery, or either 
procedure is planned during the time period of the study.
 ► Patient, who in the judgement of the investigator, may be at risk of 
dehydration or volume depletion (hypovolaemia) that may affect the patient’s 
safety and/or the interpretation of efficacy or safety data.
 ► Presence of any other medical condition that would, in the opinion of the 
investigator or their clinician, preclude safe participation in the study. This 
decision should be informed by dapagliflozin and exenatide precautions for 
use statements which will be provided to all clinicians and the research team.
 ► Alcohol consumption in excess of 21 units/week females, 28 units/week 
males.
 ► Current smoker (including electronic cigarettes) or having ceased smoking in 
the last 6 months.
 ► Any history of a pacemaker or implantable cardioverter defibrillator (ICD).
 ► Patients with a history of diabetic foot ulcers or previous (lower limb) digital 
amputations.
 ► Patients currently taking part in a structured weight loss programme such as 
weight watchers or slimming world (excluding those on weight management 
programmes as part of their diabetes care).
 ► Patients who score over 4 restraint subscale of the Dutch Eating Behaviour 
Questionnaire.
 ► Patients who score over 27 on the Binge Eating Scale.
Physical and Laboratory Test Findings
 ► ALT>3×upper limit of normal (ULN).
 ► AST>3×ULN.
 ► Bilirubin>2×ULN.
 ► Haemoglobin ≤10.5 g/dL (≤105 g/L) for men; haemoglobin ≤9.5 g/dL 
(≤95 g/L) for women.
 ► History of unexplained microscopic or macroscopic haematuria at 
screening, confirmed by follow- up sample a next scheduled visit, where 
according to the investigator a satisfactory evaluation of haematuria has not 
been conducted.
 ► Weight <60 kg and >200 kg (due to DEXA limitations).
 ► BMI <30 kg/m2 and >50 kg/m2.
 ► Recent major change in body weight (>3 kg loss or gain in preceding 
month).
Allergies and Adverse Drug Reactions
 ► Subjects with a history of any serious hypersensitivity reaction to GLP1- RA 
or SGLT2 inhibitor.
 ► Participant should have no allergies against metacresol (the preservative in 
insulin vial).
 ► History of anaphylaxis to food.
 ► Known food allergies or food intolerance.
 ► Known hypersensitivity to heparin.
 ► Known hypersensitivity to intravenous catheter equipment.
Sex and Reproductive Status
 ► Females of childbearing age who are not using adequate contraceptive 
methods or who are planning a pregnancy in the next 44 weeks (study 
duration plus 12 weeks).
 ► Women who are pregnant or breast feeding.
 ► Sexually active fertile men not using effective birth control if their partners 
are WOCBP.
Prohibited Treatments and/or Therapies
 ► Diabetes treated with pioglitazone, SGLT2 inhibitors, GLP-1 analogues or 
insulin.
 ► Treatment with SGLT2 inhibitor, GLP1 RA or subcutaneous insulin injections 
3 months before screening.
 ► Any weight loss medication (eg, orlistat) within 3 months prior to screening.
 ► Use of any drug that might affect body weight or appetite (including 
antipsychotics or corticosteroids) within 3 months prior to screening.
 ► Patients who are currently receiving a loop diuretic that cannot be 
discontinued.
Other Exclusion Criteria
 ► Active or previous substance abuse or dependence.
 ► Prisoners or subjects who are involuntarily incarcerated.
 ► Subjects who are compulsorily detained for treatment of either a psychiatric 
or physical (eg, infectious disease) illness.
 ► Dislike >25% of the study foods.
 ► Participation in other studies (within the past 30 days).
In situations where the patient has a contraindication to MR scanning, they will 
be randomised to the study but excluded from MR scanning only. The primary 
outcome measurement of fat mass can be derived from DEXA.
ALT, Alanine transaminase; AST, Aspartate transaminase; BMI, Body mass index; DEXA, dual- energy X- ray absorptiometry; eGFR, estimated glomerular filtration rate; GLP1- RA, 
glucagon- like peptide-1 receptor agonist; SGLT2i, sodium- glucose co- transporter 2 inhibitors; WOCBP, Women of childbearing potential.
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remaining timeframe of the study. Using the same clin-
ically relevant difference of 1.5 kg, significance level and 
power, the between- patient SD would be 2.42 kg, giving 
an effect size of 0.62. Assuming 80% power, a minimum 
of 33 patients per treatment arm are required. Allowing 
for an anticipated 11% attrition rate/dropout rate, a total 
of 110 patients are required (calculated using NQuery 
V.8.1.2.0).
Recruitment will take place over 44 months in Liver-
pool University Hospital NHS Foundation Trust (Aintree 
site), Liverpool, UK. Participants will be recruited either 
from existing databases of volunteer patients, diabetes 
clinics in the hospital and community and by advertise-
ment in the local press and social media.
Screening, enrolment and randomisation
After giving written informed consent, potentially eligible 
participants will attend a screening visit within 6 weeks 
prior to randomisation; this includes a medical history 
to confirm the participant’s eligibility to participate as 
determined by the inclusion/exclusion criteria (table 1), 
physical examination, blood tests, urinalysis and an ECG. 
Each participant will be informed of his/her eligibility 
for the trial once all results are available (usually within 
1 week from obtaining consent).
The randomisation for each stratum will be performed 
using computer generated (Treatment Allocation Rando-
misation System, TARDIS) random balanced blocks to 
ensure approximately equal numbers of participants 
across the treatment arms within each stratum. Each 
patient will be assigned a unique study identification 
number. The study is set- up as a double blind trial with 
both the participants, doctor, site and LCTC (Liverpool 
Clinical Trials Centre) RESILIENT trial teams being blind 
to the treatment received. Unblinded members of the 
research staff (pharmacy and selected research nurses) 
will remain the same throughout the trial. A blinded 
confirmation email will be sent to all relevant site staff and 
LCTC trial team detailing the trial number and patient 
initials. An unblinded confirmation email will also be 
sent to all relevant pharmacy staff detailing the allocated 
treatment arm, trial number and patient initials. Only the 
subject number and initials will be recorded in the elec-
tronic case report form (eCRF). All other patient identi-
fiable data will be completely anonymised. An additional 
validation check has been built into the eCRF (MACRO 
4) for authorised trial team members only to confirm 
eligibility and suitability to proceed to randomisation.
Dosage and administration of study treatments
Participants will attend once a week for administration of 
a subcutaneous injection (exenatide QW 2 mg or sham 
injection) for the duration of the study (32 weeks). The 
exenatide QW injection and the sham injection are not 
identical in appearance, so to maintain the study blinding, 
medication dispensed will be given to a member of the 
unblinded research team in an opaque bag to ensure 
the contents cannot be seen by members of the blinded 
research team or the patient. No blinded staff member 
will be allowed in the room at the time of injection and the 
injection will be disposed of by unblinded staff members 
in line with local protocols, and in a concealed manner. 
Participants will also be instructed to take a tablet with 
water (dapagliflozin 10 mg or matching placebo) each 
morning for the duration of the study, while continuing 
with their usual medication and attending for sched-
uled study visits. The number and size of tablets will be 
identical for the investigational products (dapagliflozin 
10 mg and placebo). Participants will be asked to return 
all unused investigational products, including any empty 
medication packages to the clinic at each visit. The 
subject’s compliance will be discussed at each study visit 
and assessed based on the number of injections admin-
istered and returned counts. This will be recorded in 
the defined CRF. To aid compliance, participants will be 
asked to complete a patient diary. Participants judged to 
be non- compliant may continue in the study, but will be 
counselled on the importance of taking their study medi-
cation as prescribed.
Figure 2 Study schematic.
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Study visits and procedures
Anthropometric measurements
Body weight and height, waist and hip circumference and 
whole- body bioimpedance analysis (TANITA: total body 
mass, fat percentage, fat mass, fat free mass and muscle 
mass) will be recorded. Blood pressure will be measured 
from the left arm after patients have been seated for 
5 min. The first reading will be discarded, and the mean 
of three subsequent readings recorded (table 2).
Biochemical measurements
All patients will have a routine blood sample taken for 
HbA1c, fasting plasma glucose, renal profile (to include 
electrolytes, urea and creatinine, and eGFR), lipid 
profile, liver function tests (to include ALT, AST and bili-
rubin) and insulin. Insulin sensitivity will be measured 
by Homeostatic Model Assessment for Insulin Resistance 
(HOMA- IR).18 eGFR will be estimated using the Modifi-
cation of Diet in Renal Disease (MDRD). We will measure 
fasting plasma glucose (FPG) and estimated glomerular 
filtration rate (eGFR) every 2–4 weeks. This will allow us 
to determine the amount of filtered glucose calculated 
from the product of the FPG (mg/dL) and eGFR (mL/
min/1.73 m2).
Test meal visits (visits 1, 4, 7 and 11)
Test meal visits will take place at baseline and after 4, 16 
and 32 weeks of treatment (tables 2 and 3). Participants 
will be asked to attend the investigational unit at 08:00, 
having had nothing to eat or drink other than water from 
midnight. Participants’ anthropological and biochemical 
measurements will be taken (see above). An explanation 
and demonstration of Visual Analogue Scale (VAS) ques-
tionnaires, appetite questionnaires and ventilated hood 
will be given. Additional measures taken during test meal 
days are described below.
Food intake and eating behaviour
Participants will be provided with a fixed load breakfast 
(providing 25% energy from estimated Resting meta-
bolic rate (RMR)) followed 4 hours later by an ad libitum 
lunch, which they will self- serve. The ad libitum lunch will 
consist of a multiple item buffet (eg, high and low calorie, 
sweet and savoury items) to understand how the poten-
tial satiety and reward- based changes in appetite effect 
energy intake and modify food choice. Pen and paper 
VAS measures of appetite (hunger, fullness, desire to eat, 
prospective consumption, satisfaction, thirst and nausea) 
fluctuations throughout the day will also be collected with 
retrospective appetite and craving questionnaires at the 
end of the day. Taken together, these data fully charac-
terise drug effects on appetite and eating behaviour.
A range of questionnaires assessing secondary outcomes 
of appetite, cravings, feelings of control and eating 
behaviours (including food choice) will also be completed 
at test meal visits. These include the Three Factor Eating 
Questionnaire (TFEQ)19; Power of Food Scale (PoF)20; 
the Craving for Sweet Foods sub- questionnaire from the 
Health and Tastes Attitude Scale (HTAS)21; the 7- day 
Control of Eating Questionnaire (COEQ)22; the external 
eating subscale from the Dutch Eating Behaviour Ques-
tionnaire (DEBQ)23 assessing external eating; and the 
Mindful Eating Scale (MES)24 describing the physical and 
emotional sensations associated with eating.
Indirect calorimetry
Energy expenditure and respiratory quotients will be 
measured on the morning of the test meal visit prior to 
the fixed energy breakfast using an indirect calorimeter 
(GEM Nutrition, Daresbury, UK) fitted with a ventilated 
hood and derived using the modified Weir equation.16 
Participants will remain awake but motionless in a supine 
position for 45 min with RMR calculated from respiratory 
data averaged over the final 30 min of assessment. The 
first 15 min of each measurement will be discarded to 
allow for complete acclimatisation to the hood and the 
recumbent position.
Physical activity monitoring
Habitual physical activity will be monitored using a Sense-
Wear mini armband (BodyMedia, Pittsburgh, Pennsyl-
vania, USA) for a 4- day period (to include one weekend 
day) during weeks 0, 4, 16 and 32. Data collected from 
the SenseWear device include daily average step count, 
total energy expenditure, active energy expenditure and 
time spent in domains of physical activity including sleep, 
lying, sedentary (<1.5 metabolic equivalents, METS), 
light (1.5–3 METS), moderate (3–6 METS), vigorous 
(6–9 METS) and very vigorous (>9 METS) and is analysed 
using SenseWear Professional software (V.8.0).
Food diaries
Participants will be asked to complete a food diary 
detailing exactly what they eat and drink over the same 
4 day period. Total energy consumption, carbohydrate, 
protein and fat content will be determined from dietary 
records using Nutritics (Nutrition Analysis Software for 
Professionals).
Baseline and end of treatment measures
Body composition
All participants will undertake a full body DEXA (Lunar 
IDXA, GE Healthcare, Amersham, UK) scan after an 
overnight fast at baseline and week 32. Body composition 
will be determined to quantify total and regional (trunk, 
limb, android and gynoid) fat mass and fat- free mass.
MRI measures of body composition, hepatic and pancre-
atic fat MRI eligible participants will be scanned using a 
3.0 T Siemens Prisma scanner (Siemens Medical Solu-
tions, Erlangen, Germany) at the Liverpool MRI Centre 
(LiMRIC). Images are obtained with the patient supine 
and using an integrated body coil (Siemens Medical Solu-
tions, Erlangen, Germany).
For body composition, multiple blocks of contiguous 
slices using a Dixon VIBE in and out of phase sequence 
will be conducted to produce fat and water images from 
the vertex of the skull to the knees. These will be used to 
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Table 2 Assessments and procedures during screening and study visits (D, day; W, week)





























Visit (fasting) 0   1 and 
2
3 4 5 6 7 8 9 10 11 and 12
Informed consent X       
Medical history/
demographics
X       
Physical examination and 
ECG
X       
Pregnancy test X   X   
Glucometer dispensing 
and training
X       
Urinalysis X       
Height X       
Weight X   X X X X X X X X X X
Waist and hip 
measurements
  X X X X X X X X X X
Bioelectrical impedance 
analysis (BIA)
  X X X X X X X X X X
BP, pulse X   X X X X X X X X X X
Blood tests X   X X X X X X X X X X
Dapaglifozin/placebo 
dispensing
  X X X X X X X X X
Concomitant medication 
check
X   X X X X X X X X X X
Compliance check     X X X X X X X X X
AE reporting   X X X X X X X X X X
24- hour urine   X X X X
4- day food diary   X X X X
4- day activity monitoring   X X X X
Test meal   X X X X
Indirect calorimetry   X X X X
Psychological 
questionnaires and VAS
  X X X X
DEXA   X X
MRI (full body, liver fat, 
pancreatic fat)
  X X
MRI cardiac   X X
fMRI and eye- tracking X   X
FMD   X X
Cardiac ECHO   X X
DLW and additional DEXA X X X X X
Euglycaemic clamps   X X
*Not including administration of weekly exenatide QW/sham injection.
AE, adverse event; BIA, bioelectrical impedance analysis; BP, blood pressure; DEXA, dual- energy X- ray absorptiometry; DLW, doubly labelled 
water; ECG, electrocardiogram; FMD, flow- mediated dilatation; fMRI, functional MRI; VAS, Visual Analogue Scale.
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determine fat volumes in abdomen and neck. For hepatic 
fat, a multi- echo Dixon sequence with blocks of contig-
uous slices and breath holds on expiration will be used to 
image the abdomen. A single transverse slice that inter-
sects the porta- hepatis will be positioned and a multi- echo 
gradient- echo image will be acquired to determine a liver 
fat fraction. For the assessment of pancreatic fat, circular 
regions of interest (~100 mm2) will be drawn in the head, 
body and tail of the pancreas of two representative slices, 
with fat fraction calculated as the average across both 
slices.
Exploratory outcomes
All participants will be offered the opportunity to take 
part in several optional study visits with a view to 20 partic-
ipants completing each treatment ARM. Uptake to these 
optional visits will be determined by eligibility, specifically 
contraindications to MR scanning and patient choice.
A. Euglycaemic–hyperinsulinaemic clamp: A subset of par-
ticipants will take part in a two- stage, low- dose and 
high- dose euglycaemic–hyperinsulinaemic clamp 
combined with a [6,6 2H2] glucose infusion, at base-
line and week 32 (described in detail in Cuthbertson 
et al25). Briefly, a primed continuous infusion of [6,6 
2H2] glucose will be administered intravenously for 
6 hours. After 2 hours, insulin infusion at 0.5 mU·kg-
1·min-1 (low- dose) will be administered for 2 hours 
to measure the insulin sensitivity of endogenous glu-
cose production (EGP); then insulin infusion at 1.5 
mU·kg-1·min-1 (high- dose) will be administered for 
2 hours to measure insulin sensitivity of peripheral 
glucose uptake (Rd). Euglycaemia will be maintained 
by adjusting a 20% glucose infusion, spiked with glu-
cose (7 mg·g−1 for low dose, 10 mg·g−1 for high dose) 
according to 5 min plasma glucose measurements us-
ing a glucose oxidase method (Yellow Springs Analy-
ser). Blood samples will be obtained before the start 
of the tracer infusions, every 10 min during the final 
30 min of the basal period, low- dose and high- dose 
steady state of the clamp procedure, and every 30 min 
between these periods. The isotopic enrichment of 
plasma glucose will be determined by gas chromatog-
raphy mass spectrometry at the Wolfson Centre for 
Translational Research, Postgraduate Medical School, 
University of Surrey, UK.
B. Doubly labelled water (DLW): A subset of participants 
will undertake the doubly labelled water method com-
Table 3 Test meal guidelines
Time point guidelines Procedure
Arrival 08:00* Blood sample taken.
Subjects asked to empty bladder; start of timed 24- hour urine collection.
Weight, waist circumference, bioelectrical impedance analysis, pulse and blood 
pressure taken.
08:10 Basal metabolic rate measurement (indirect calorimetry—see below for details).
08:55 (T1 VAS) Subjects will complete a pre- breakfast, seven- component VAS questionnaire to 
measure hunger and other subjective variables.
09:00 Subjects will be provided with a fixed- quantity breakfast, consisting of cornflakes with 
milk, toast and preserve, tea/coffee and orange juice.
09:20 (T2 VAS) Subjects will complete a post- breakfast, 7- component VAS questionnaire to measure 
hunger and other subjective variables.
10:00, 11:00, 12:00 (T3-5 VAS)
Administered at hourly intervals (from 
pre- breakfast VAS) for 3 hours
Subjects will complete the same seven- component VAS questionnaire as used pre- 
breakfast, providing a pre- meal set of ratings.
12:55 (T6 VAS) Subjects will complete a pre- lunch, seven- component VAS questionnaire to measure 
hunger and other subjective variables.
13:00 Subjects will be given an ad libitum lunch. The meal consists of a multiple item buffet 
(mix of high- fat and low- fat savoury items) and subjects may eat ad lib, and signal when 
they have finished the meal.
13:30 (T7 VAS) Subjects will complete a post- lunch, seven- component VAS questionnaire to measure 
hunger and other subjective variables.
Participants also complete a post- lunch palatability VAS.
14:00, 15:00, 16:00, 17:00 (T8-11 
VAS)
Administered at hourly intervals (from 
pre- breakfast VAS) for 4 hours
Subjects will complete the same seven- component VAS questionnaire as used pre- 
breakfast, providing a post- meal set of ratings.
*Timings will be adjusted to facilitate an amended arrival time. All events will remain at the same relative intervals.
VAS, Visual Analogue Scale.
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bined with a DEXA scan, at weeks 0, 4, 16 and 32 to 
assess mean energy expenditure over a 2- week period. 
Participants will drink from a stock solution of 2H2O 
(99% enrichment) and H2
18O (10% enrichment) at a 
dose of 1 g·kg-1. Spot urine samples will be collected 
at 1.5- hour intervals on the day of DLW administra-
tion, followed by once daily for 13 days. Isotopic en-
richments of the urine samples will be measured by 
isotope ratio mass spectrometry at The National In-
stitute of Diabetes and Digestive and Kidney Disease 
(NIDDK), Bethesda, USA.
C. Endothelial function and vascular structure: A 10 MHz 
multifrequency linear array probe attached to a high- 
resolution ultrasound machine (Siemens Medical 
Solutions, Malvern, Pennsylvania, USA) will be used 
to image the carotid artery and the brachial artery (in 
the distal third of the upper right arm) at baseline and 
week 32 in a subset of participants. Nitric oxide–me-
diated endothelial function will be assessed by mea-
suring flow- mediated dilatation (FMD) in response to 
a 5 min ischaemic stimulus, induced by forearm cuff 
inflation.26 Peak brachial artery diameter and blood 
flow velocity, and the time taken to reach these peaks 
following cuff release will be recorded. The structure 
of the carotid artery will be measured as the intima- 
media thickness (cIMT), or artery wall thickness using 
custom software.27
D. Cardiac structure and function: Indices of myocardial sys-
tolic and diastolic function will be determined using 
2D and tissue Doppler echocardiography.28 All echo-
cardiograms will be performed using a GE E95 ma-
chine with an M5SC- D 2.5 MHz phased array transduc-
er, measuring left ventricular (LV) dimensions during 
diastole and systole and wall thicknesses and LV mass; 
LV and ejection fraction (modified Simpson’s biplane 
method); left atrial volumes; mitral inflow peak early 
diastolic velocity (E), peak late diastolic velocity (A), 
E/A ratio and E wave deceleration time. Tissue Dop-
pler mitral annular early diastolic velocity (E′) will be 
assessed at septal and lateral sites, and averaged for 
calculation of E/E′. Global longitudinal strain will be 
derived from apical 4- chamber, apical 2- chamber and 
apical long axis images. All data will be analysed using 
Echopac (V.9: GE, Horten, Norway).
E. Cardiac MRI: A subset of participants will undertake 
cardiac magnetic resonance at baseline and week 32 
using the same MRI scanner described combined 
with ECG gating. A gadolinium- based contrast agent 
(Gadovist, Bayer) will be administered via a cannula 
in the forearm to facilitate imaging. A 2.5 mL blood 
sample will be collected to measure the haemato-
crit. Strain and peak early diastolic strain rate will 
be quantified from tagging and cine images using 
InTag ( www. creatis. insa- lyon. fr/ inTag/) and feature 
tracking, respectively. LV volumes, mass and function 
will be calculated using commercially available non- 
proprietary software. Tissue characterisation will be 
performed using standard T1 mapping (correcting 
for haematocrit) and late gadolinium enhancement 
techniques.
F. Functional Magnetic Resonance Imaging (fMRI): Using 
the same MRI scanner, a subset of participants will un-
dergo fMRI to examine neural processing in response 
to tasks that assess reward related function (Passive- 
Viewing) and inhibitory control (Stop- Signal Task).29 
Using the test- meal protocol described earlier, BOLD 
imaging will be conducted in patients under fasted 
(pre- lunch) and sated (post- lunch) states both at base-
line and week 32. The fMRI data will be imported to 
and analysed using Statistical Parametric Mapping soft-
ware (SPM12, University College London, UK) and 
custom built MATlab scripts (The MathWorks, Massa-
chusetts, USA). Appetite will be measured throughout 
the scanning day using a VAS.
Monitoring/dispensing visits (1, 4, 5, 6, 7, 8, 9, 10)
These visits will involve a brief consultation with the 
study team to review glycaemic control (self- monitored 
capillary blood glucose), adverse effects and compliance 
(tablet count), and to collect supply of medication. All 
injections of exenatide QW/placebo will be administered 
weekly by unblinded staff members at site and recorded. 
Unblinded members of the research team will have no 
role in assessment of participants outside of these speci-
fied roles as detailed in the trial delegation log.
Pharmacovigilance
All adverse events will be reported and assignment 
of the severity/grading (mild, moderate, severe, life- 
threatening, death) made by the investigator respon-
sible for the care of the participant. The assignment of 
causality will be made by the investigator. All non- serious 
adverse events (SAEs), whether expected or not, will be 
recorded and updated at each study visit. All new SAEs 
will be reported from the point of consent until 28 days 
after discontinuation of the investigational medical 
product; this includes those thought to be associated with 
protocol- specified procedures. Investigators will report 
SAEs, serious adverse reactions (SARs) and sudden 
unexpected adverse reactions (SUSARs) to LCTC within 
24 hours of the local site becoming aware of the event. 
LCTC will notify the Medicines and Healthcare products 
Regulatory Agency (MHRA) and main Research Ethics 
Committee (REC) of all SUSARs occurring during the 
study: fatal and life- threatening SUSARs within 7 days of 
notification and non- life- threatening SUSARs within 15 
days. All adverse events will be followed until satisfactory 
resolution or until the investigator responsible for the 
care of the participant deems the event to be chronic or 
the patient to be stable.
Trial monitoring and oversight committees at LCTC
The RESILIENT study will have a Trial Management 
Group (TMG), Trial Steering Committee (TSC) and an 
Independent Safety and Data Monitoring Committee 
(ISDMC) to monitor study progress.
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The TMG, supported by the LCTC, will be responsible 
for the day- to- day running and management of the trial 
and will consist of the protocol committee members and 
the trial manager. The TSC will provide oversight of the 
study, concentrating on progress of the study, adherence 
to protocol, participant’s safety and consideration of new 
information, making recommendations on study pathway 
modifications and continuation of the study. The TSC will 
include experienced lay members of the public, other 
medical experts and clinical trialists. Meetings will be 
held at regular intervals determined by need, but no less 
than once a year. The ultimate decision for the continua-
tion of the trial lies with the TSC.
The ISDMC will be responsible for reviewing and 
assessing recruitment, interim monitoring of safety 
and effectiveness, trial conduct and external data. The 
ISDMC will also provide recommendations to the TSC 
concerning continuation of the study.
Outline of analysis
General approach
Categorical variables will be summarised as frequency 
(%), and continuous variables will be summarised as 
mean (SD) or median (IQR) depending on the distribu-
tion. Full details of the planned statistical analysis will be 
included in a separate statistical analysis plan to be devel-
oped in the months following trial opening and will be 
approved by both the ISDMC and the TSC.
Subgroup analysis
No subgroup analysis is planned for this trial.
Significance levels
For the analysis of the primary outcome, statistical signifi-
cance will be tested using Hochberg’s procedure, a hierar-
chical analysis approach for the primary outcomes of (1) 
exenatide QW and dapagliflozin compared with placebo 
control, (2) dapagliflozin alone compared with placebo 
control. Here comparisons will be ordered (descending) 
in terms of their significance level and assessed using a 
p value <0.05 to determine statistical significance for the 
first comparison and p<0.025 for the second.
The main analysis for primary and secondary endpoints 
will use the full analysis set, consisting of all randomised 
patients, with participants analysed according to the 
group to which they were originally allocated, and with 
outcomes included irrespective of protocol adherence, in 
order to follow the intention- to- treat principle. The safety 
population, consisting of all patients who actually receive 
a trial intervention, according to the treatment received, 
will be used for analysis of toxicity and adverse events.
Missing data
Missing data are assumed to be small and analysis will be 
carried out on a complete case basis. If there are a signif-
icant number of missing entries on any endpoint (>20% 
for example), missing data shall be estimated using 
multiple imputation based on the method of chained 
equations.
Analysis
For analysis of the primary endpoint, the mean differ-
ence from baseline and week 32 will be presented with 
a corresponding 95% CI. Between- group differences will 
be analysed using linear regression techniques, analysing 
the week 32 values while including baseline covariate 
value. The effect of dapagliflozin will be estimated by 
contrasting (1) control arm versus dapagliflozin arm. 
The effect of exenatide will be estimated by comparing 
(2) dapagliflozin versus dapaglifozin and exenatide.
Secondary analyses
Analyses of all secondary endpoints are continuous and anal-
ysis techniques shall replicate that of primary endpoints.
Safety analysis
Information relating to adverse events (including events 
relating to hypoglycaemia, gastrointestinal upset, and 
urinary and genital tract infections) will be tabulated and 
summarised descriptively. Continuous laboratory values 
will be summarised as described above.
ETHICS AND DISSEMINATION
This study is being conducted in accordance with Good 
Clinical Practice (GCP), as defined by the International 
Conference on Harmonisation (ICH) and in compliance 
with the European Union Directive 2001/20/EC trans-
posed into UK law as statutory instrument 2004 No 1031: 
Medicines for Human Use (Clinical Trials) Regulations 
2004 and all subsequent amendments and the US Code 
of Federal Regulations, Title 21, Part 50 (21CFR50). 
The trial protocol has received the favourable opinion 
of the NRES North West/Liverpool Central Research 
Ethics Committee (14/NW/1147; protocol number UoL 
001187). An appropriate patient information sheet and 
consent forms describing in detail the trial interventions/
products, trial procedures and risks were approved by the 
ethical committee (IEC), and the patients are asked to 
read and review the document. The investigator explains 
the study to the patient and answer any questions posed. 
A contact point where further information about the trial 
may be obtained is provided. After being given adequate 
time to consider the information, the patient is asked 
to sign the informed consent document. A copy of the 
informed consent document is given to the patient for 
their records and a copy placed in the medical records, 
with the original retained in the investigator site file. 
The patient may withdraw from the trial at any time by 
revoking the informed consent. The rights and welfare 
of the patients are protected by emphasising to them that 
the quality of medical care will not be adversely affected if 
they decline to participate in this study.
REGULATORY APPROVAL
This trial has been registered with the MHRA and has 
been granted a Clinical Trial Authorisation (CTA). The 
CTA reference is its EudraCT number: 2013-004264-60.
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PUBLICATION
The results will be analysed together and published as 
soon as possible. The uniform requirements for manu-
scripts submitted to biomedical journals (http:// www. 
icmje. org/) will be respected. The ISRCTN allocated to 
this trial would be attached to any publications resulting 
from this trial.
TRIAL STATUS
The trial opened for recruitment at University Hospital 
Aintree in Liverpool on 25 October 2017. Recruitment is 
ongoing at the time of publication with the anticipated 
trial completion (last patient last visit) in October 2021.
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